Review
Biochemistry & Molecular Biology
Marilyn Hagan, Bu' Hussain Hayee, Ana Rodriguez-Mateos
Summary: Polyphenols (PPs) may have therapeutic benefits in gastrointestinal (GI) disorders like IBS or IBD, but the evidence base is inconsistent and further research is needed to clarify their effects.
Article
Gastroenterology & Hepatology
Qi Su, Hein M. Tun, Qin Liu, Yun Kit Yeoh, Joyce Wing Yan Mak, Francis K. L. Chan, Siew C. Ng
Summary: This study examined the association between gut microbiota and Irritable bowel syndrome (IBS) subtypes, and found that there are distinct differences in microbiota composition among different IBS subtypes. The microbial diversity is significantly reduced in IBS-D and IBS-U, but not in IBS-C. The study also identified microbial signatures associated with depression in IBS patients. Factors such as gender, age, and dietary patterns have significant effects on gut microbiota in different IBS subtypes. These findings emphasize the importance of personalized gut microbiome modulation approaches for optimal therapeutic effects in different subtypes of IBS.
Review
Food Science & Technology
Ao Liu, Wenkang Gao, Yixin Zhu, Xiaohua Hou, Huikuan Chu
Summary: Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder that significantly affects personal health and imposes a substantial economic burden on society. Emerging evidence suggests that IBS is associated with gut microbial dysbiosis, including not only bacteria but also fungi, viruses, archaea, and other parasitic microorganisms. Fungi and methanogens play a role in diagnosis and treatment of IBS.
Article
Microbiology
Jonathan P. P. Jacobs, Venu Lagishetty, Megan C. C. Hauer, Jennifer S. S. Labus, Tien S. S. Dong, Ryan Toma, Momchilo Vuyisich, Bruce D. D. Naliboff, Jeffrey M. M. Lackner, Arpana Gupta, Kirsten Tillisch, Emeran A. A. Mayer
Summary: This study used multi-omics assessment methods to explore the changes in gut microbiome function in irritable bowel syndrome (IBS), and identified new microbial biomarkers. The findings support the application of integrated assessment of microbial function in IBS research, and contribute to the discovery of novel microbiome-related therapeutic targets.
Article
Dermatology
Khalaf Kridin, Ralf J. Ludwig
Summary: Isotretinoin does not increase the risk of Crohn's disease, but it may be associated with a slight and temporary increase in the risk of ulcerative colitis. However, it can lower the risk of irritable bowel syndrome.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2023)
Article
Health Care Sciences & Services
Yuhan Fu, Michael Kurin, Marc Landsman, Ronnie Fass, Gengqing Song
Summary: The aim of the study was to determine whether IBS is an independent risk factor for developing opioid addiction and related gastrointestinal symptoms in patients with IBD. The results showed that patients with concomitant IBD and IBS were more likely to be prescribed oral opioids and develop opioid dependence or abuse.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Review
Biochemistry & Molecular Biology
Mariusz A. Bromke, Malgorzata Krzystek-Korpacka
Summary: Inflammatory bowel disease, characterized by chronic and complex conditions such as ulcerative colitis or Crohn's disease, is closely linked to dysregulation of the mucosal immune system, compromised intestinal epithelial barrier, and dysbiosis of the gut microbiome. Bile acids play a significant physiological role beyond aiding digestion of lipids, acting as signaling molecules on lipid metabolism and immune responses through various receptors. Recent studies have focused on the therapeutic potential of bile acids in the treatment of inflammatory bowel disease, highlighting their impact on gut microbiome and signaling pathways.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Gastroenterology & Hepatology
Hana Cipcic Paljetak, Anja Baresic, Marina Panek, Mihaela Peric, Mario Matijasic, Ivana Lojkic, Ana Barisic, Darija Vranesic Bender, Dina Ljubas Kelecic, Marko Brinar, Mirjana Kalauz, Marija Milicevic, Dora Grgic, Niksa Turk, Irena Karas, Silvija Cukovic-Cavka, Zeljko Krznaric, Donatella Verbanac
Summary: This study compares the differences in gut microbiota between newly diagnosed, treatment-naive adult inflammatory bowel disease (IBD) patients (CD and UC) with irritable bowel syndrome (IBS) patients and healthy individuals. The results show that changes in gut microbiota are detectable at the onset of disease and may play a significant role in the development of IBD.
Review
Gastroenterology & Hepatology
Arjun Gandhi, Ayesha Shah, Michael P. Jones, Natasha Koloski, Nicholas J. Talley, Mark Morrison, Gerald Holtmann
Summary: The systematic review and meta-analysis indicated that methane-positive SIBO is more prevalent in IBS, particularly in IBS-C, compared to controls, while it is less common in patients with IBD. In patients with IBD, methane-positive SIBO was significantly lower in Crohn's disease compared to ulcerative colitis. More studies are needed to establish a causal relationship due to the low quality of evidence and clinical heterogeneity in the current studies.
Article
Health Care Sciences & Services
Zahra A. Barandouzi, Joochul Lee, Kendra Maas, Angela R. Starkweather, Xiaomei S. Cong
Summary: The study compared food components and gut microbiota patterns between IBS patients and healthy controls, finding higher alpha diversity indices and altered gut microbiota in IBS patients. High microbial diversity and alterations in gut microbiota composition were observed in IBS individuals with high caffeine consumption, suggesting a potential link between caffeine intake and gut microbiome patterns.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Psychology, Biological
Andre Schulz, Sina-Katharina Welsch, Sarah Etringer, Greta Hansen, Lea Milbert, Jochen Schneider, Gennaro Taddei, Raquel Gomez Bravo, Charilaos Lygidakis, Zoe van Dyck, Annika Lutz, Paul Wilmes, Claus Vogele
Summary: This study investigates whether IBD and IBS patients have altered perception of 'natural' gastric distensions. The results show that IBD patients drink significantly more water until satiation than IBS patients, suggesting relative gastric hypersensitivity in IBS and relative hyposensitivity in IBD patients.
PHYSIOLOGY & BEHAVIOR
(2023)
Article
Gastroenterology & Hepatology
Adrienne Lenhart, Tien Dong, Swapna Joshi, Nancee Jaffe, Charlene Choo, Cathy Liu, Jonathan P. Jacobs, Venu Lagishetty, Wendy Shih, Jennifer S. Labus, Arpana Gupta, Kirsten Tillisch, Emeran A. Mayer, Lin Chang
Summary: This study found that restrictive diets are more likely to be consumed by irritable bowel syndrome (IBS) patients than healthy controls (HCs) to reduce the severity of gastrointestinal symptoms. Dietary patterns influence the composition of the fecal microbiota and may explain some of the differences between IBS and HCs.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Heidi M. Staudacher, Sophie Mahoney, Kim Canale, Rachelle S. Opie, Amy Loughman, Daniel So, Lauren Beswick, Chris Hair, Felice N. Jacka
Summary: A Mediterranean diet is feasible and effective in improving gastrointestinal and psychological symptoms in patients with IBS.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Gastroenterology & Hepatology
Zlatan Mujagic, Melpomeni Kasapi, Daisy M. A. E. Jonkers, Isabel Garcia-Perez, Lisa Vork, Zsa Zsa R. M. Weerts, Jose Ivan Serrano-Contreras, Alexandra Zhernakova, Alexander Kurilshikov, Jamie Scotcher, Elaine Holmes, Cisca Wijmenga, Daniel Keszthelyi, Jeremy K. Nicholson, Joram M. Posma, Ad A. M. Masclee
Summary: Combining microbiome and metabolome data can distinguish between irritable bowel syndrome (IBS) patients and healthy controls. Unsupervised clustering based on fecal microbiome-metabolome data revealed distinct subsets of IBS patients. The study also found associations between altered serotonin metabolism, unfavorable stress response related to gastrointestinal symptoms, and IBS, supporting the importance of the microbiome-gut-brain axis in the pathogenesis of IBS.
Review
Nutrition & Dietetics
Yunyao Qu, Si Hong Park, David C. Dallas
Summary: This review discusses the potential of kappa-casein glycomacropeptide (GMP) in regulating the gut microbiome and its impact on gut health, as well as its potential clinical application in treating irritable bowel syndrome (IBS).
Review
Gastroenterology & Hepatology
Brigida Barberio, David J. Gracie, Christopher J. Black, Alexander C. Ford
Summary: This study conducted a network meta-analysis to compare the relative efficacy of various biological therapies and small molecules in the treatment of luminal Crohn's disease. The results showed differences in the effectiveness of different drugs in inducing and maintaining clinical remission, and previous exposure to biologics also had an impact on treatment outcomes.
Letter
Gastroenterology & Hepatology
Conchubhair Winters, Alexander Charles Ford
Review
Gastroenterology & Hepatology
Brigida Barberio, Pierfrancesco Visaggi, Edoardo Savarino, Nicola de Bortoli, Christopher J. Black, Alexander C. Ford
Summary: This study conducted a network meta-analysis to evaluate the efficacy and safety of different medical therapies for endoscopy-negative reflux disease. The results showed that proton pump inhibitors (PPIs) are superior to other drugs in treating this condition. Future research should focus on better patient classification and investigating the efficacy of other drugs.
NEUROGASTROENTEROLOGY AND MOTILITY
(2023)
Review
Gastroenterology & Hepatology
Shahida Din, Christian P. Selinger, Christopher J. Black, Alexander C. Ford
Summary: A network meta-analysis was conducted to examine the risk of Herpes zoster infection associated with biologics and small molecules used to treat inflammatory bowel disease (IBD). The results showed that Janus kinase inhibitors, particularly tofacitinib, were most likely to increase the risk of Herpes zoster infection, and the risk increased with higher doses.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Oncology
Dion Morton, Matthew Seymour, Laura Magill, Kelly Handley, James Glasbey, Bengt Glimelius, Andy Palmer, Jenny Seligmann, Soren Laurberg, Keigo Murakami, Nick West, Philip Quirke, Richard Gray, FOxTROT Collaborative Grp
Summary: Neoadjuvant chemotherapy shows potential benefits for locally advanced colon cancer compared to postoperative chemotherapy. In this study, patients with radiologically staged T3-4, N0-2, M0 colon cancer were randomly assigned to receive 6 weeks of preoperative oxaliplatin-fluoropyrimidine chemotherapy followed by either 18 or 24 weeks postoperatively. Results indicate that neoadjuvant chemotherapy results in marked downstaging of tumors and lower rates of incomplete resections and disease recurrence within 2 years.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Gastroenterology & Hepatology
Hideki Ueno, Iris D. Nagtegaal, Philip Quirke, Kenichi Sugihara, Yoichi Ajioka
Summary: Tumor deposits (TDs), discontinuous tumor spread, negatively impact survival in approximately 20% of colorectal cancer patients. Revisions on TD definition and categorization in the TNM system have been partially successful, but alternative staging methods, such as the counting method, have shown superior prognostic and diagnostic value. An international discussion on optimal TD treatment is needed to ensure patients receive the best possible adjuvant treatment.
ANNALS OF GASTROENTEROLOGICAL SURGERY
(2023)
Letter
Gastroenterology & Hepatology
Maria rosa Ingrosso, Christopher j. Black, Alexander c. Ford
Article
Gastroenterology & Hepatology
Christy Riggott, Keeley M. Fairbrass, Christopher J. Black, David J. Gracie, Alexander C. Ford
Summary: Using latent class analysis, this study identified novel clusters of patients with inflammatory bowel disease (IBD) and found that patients with higher gastrointestinal and psychological symptoms were at a higher risk of adverse disease outcomes and were also high-volume users of healthcare.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Editorial Material
Gastroenterology & Hepatology
Kee-Huat Chuah, Christopher J. Black, Vincent Tee, Sze-Zee Lim, Wen-Xuan Hian, Nur-Fazimah Sahran, Yeong-Yeh Lee, Sanjiv Mahadeva, Alexander C. Ford
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Review
Gastroenterology & Hepatology
Vivek C. Goodoory, Mais Khasawneh, Christopher J. Black, Eamonn M. M. Quigley, Paul Moayyedi, Alexander C. Ford
Summary: This article conducted a meta-analysis to study the efficacy of probiotics in the treatment of irritable bowel syndrome (IBS). The study found that certain combinations of probiotics or strains may be beneficial for IBS, but the certainty of the evidence was low.
Review
Gastroenterology & Hepatology
Pierfrancesco Visaggi, Brigida Barberio, Giulio Del Corso, Nicola de Bortoli, Christopher J. Black, Alexander C. Ford, Edoardo Savarino
Summary: A network meta-analysis was conducted to compare the efficacy of different drugs for active eosinophilic esophagitis (EoE). The results showed that most available drugs were more effective than placebo in treating EoE. However, significant heterogeneity among the trials hindered the establishment of a solid therapeutic hierarchy.
Article
Gastroenterology & Hepatology
Christy Riggott, Keeley M. Fairbrass, Christian P. Selinger, David J. Gracie, Alexander C. Ford
Summary: The use of opioids in patients with inflammatory bowel disease (IBD) is associated with psychological comorbidity and an increased risk of intestinal resection, particularly with stronger formulations. Future studies should classify the risks of different opioids to develop reliable prescribing algorithms, and evaluate the effectiveness of addressing psychological factors as an opioid avoidance strategy in routine IBD care.
INFLAMMATORY BOWEL DISEASES
(2023)
Letter
Oncology
Richard Gray, Matt Seymour, Laura Magill, Kelly Handley, Philip Quirke, Nick West, Dion Morton
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Surgery
Morten F. S. Hartwig, Mustafa Bulut, Jens Ravn-Eriksen, Lasse B. Hansen, Rasmus D. Bojesen, Mads Falk Klein, Henrik L. Jakobsen, Morten Rasmussen, Bo Rud, Jens-Ole Eriksen, Susanne Eiholm, Anne-Marie K. Fiehn, Phil Quirke, Ismail Gogenur
Summary: The study aimed to assess the feasibility of Combined Endoscopic and Laparoscopic Surgery (CELS) in high-risk patients with early colon cancer. The results showed that CELS resection was feasible in selected patients and could spare some patients from undergoing large bowel resection.
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
(2023)
Meeting Abstract
Gastroenterology & Hepatology
Mais Khasawneh, Orla F. Craig, David J. Gracie, Christopher J. Black, Alexander C. Ford